AbbVie Inc. reports pharmaceutical developments across immunology, neuroscience, oncology and Allergan Aesthetics. Recurring updates include financial results by product portfolio, clinical and real-world data for therapies such as SKYRIZI and RINVOQ, FDA regulatory submissions and response letters, and medical-conference presentations in inflammatory bowel disease and other immune-mediated conditions.
Company news also covers pipeline spending, acquired in-process research and development, manufacturing capacity for medicines in core therapeutic areas, and investor conference appearances. AbbVie’s product references commonly include SKYRIZI, RINVOQ, Botox Therapeutic, Vraylar, Ubrelvy, Qulipta, Venclexta, Imbruvica and Elahere.
AbbVie (ABBV) presented Phase 3 RINVOQ results showing continued facial and total body repigmentation in non-segmental vitiligo through week 76.
Among patients continuing 15 mg once daily, facial response rates rose from 33.1% at week 48 to 55.1% in Viti-Up-1 and from 27.6% to 47.4% in Viti-Up-2. Total body response rates rose from 29.2% to 42.5% and from 26.2% to 40.1%, respectively. Responses mean at least 75% improvement in facial scores or 50% in total body scores from baseline. These were observed-case results from an open-label extension.
A 28-week substudy involving 84 adults found numerically higher responses with RINVOQ plus narrowband ultraviolet B phototherapy than RINVOQ alone. No new safety signals were reported. RINVOQ is EU-approved for patients aged 12 and older who are candidates for systemic therapy; its use in non-segmental vitiligo remains under U.S. FDA review.
AbbVie (ABBV) will announce its third-quarter 2026 financial results on October 30, 2026, before the market opens.
The earnings conference call will be webcast live at 8 a.m. Central time through investors.abbvie.com. An archived edition will be available later that day.
AbbVie (ABBV) announced detailed Phase 1 results for investigational ABBV-295, showing weight reduction across weekly and less frequent dosing regimens. The EASD 2026 presentation covers 60 participants randomized to ABBV-295 or placebo for 12 or 13 weeks. Mean body mass index was 29.3 kg/m2, and 88% were male.
Adjusted mean weight changes were -7.8% to -9.8% at Week 12 with weekly dosing, and -9.7% and -7.9% at Week 13 with every-other-week and monthly dosing, respectively, versus approximately -0.3% for placebo. Mean half-life, the time for drug levels to fall by half, ranged from 10.7 to 12.3 days. No serious treatment-emergent adverse events occurred. Nausea affected 33.3% versus 20.0% with placebo; diarrhea affected 20.0% versus 0.0%. Gastrointestinal events led to discontinuation in 4.4% versus 0.0%. AbbVie plans to advance the therapy into Phase 2 for chronic weight management.
AbbVie (ABBV) reported that all three zumilokibart dose regimens met the primary endpoint in the Phase 2 APEX Part B study.
The ongoing study evaluated 346 adults with moderate to severe atopic dermatitis. At Week 16, all regimens produced statistically significantly higher EASI-75 response rates—at least 75% improvement in eczema extent and severity from baseline—versus placebo. All doses also showed statistically significant improvements in near-complete or complete skin clearance and itch versus placebo. The mid-dose regimen showed greater reductions in skin severity at Week 1 and itch at Week 2 versus placebo and was selected for Phase 3 development.
The most common treatment-emergent adverse events through Week 16, occurring in ≥5% of any treatment group, included nasopharyngitis, headache, noninfective conjunctivitis, upper respiratory tract infection, atopic dermatitis and urinary tract infection.
AbbVie (ABBV) will present dermatology research at the 2026 EADV Congress, held September 30–October 3 in Vienna, Austria. The program includes 60 abstracts, with three late-breaking presentations, covering approved therapies risankizumab and upadacitinib and investigational compounds lutikizumab and zumilokibart.
Presentations include 52-week upadacitinib data from the Phase 3 UP-AA alopecia areata trials and primary 16-week results from the Phase 2 APEX Part B zumilokibart study in moderate-to-severe atopic dermatitis. Lutikizumab presentations address inflammation, symptoms and disease burden in hidradenitis suppurativa. Other research covers upadacitinib in non-segmental vitiligo, including week 76 repigmentation response, and risankizumab in psoriasis, including pediatric patients and a comparison with deucravacitinib. A KEEPsAKE-1 analysis examines joint damage progression in psoriatic arthritis.
AbbVie (ABBV) has partnered with Valkai to apply artificial intelligence in targeted areas of its clinical development work. AbbVie plans to deploy Valkai’s AI capabilities to help clinical research teams generate insights faster and spend less time on manual processes. The company sees opportunities to shorten development timelines, but describes these as potential benefits rather than measured results.
AbbVie (ABBV) received U.S. FDA approval for JUVMO (tavapadon), a once-daily treatment for adults with Parkinson's disease.
The selective D1/D5 receptor agonist can be taken with or without oral levodopa. AbbVie expects U.S. patient availability in October 2026. In the Phase 3 TEMPO-1 and TEMPO-2 trials of early Parkinson's disease, JUVMO improved daily-function scores versus placebo at week 26. In TEMPO-3, patients taking JUVMO with levodopa gained 1.7 hours of daily “on” time without troublesome involuntary movements, versus 0.6 hours for placebo with levodopa at week 26. Daily “off” time fell by 1.9 and 0.9 hours, respectively.
Among participants who continued treatment for 85 weeks, 93% taking JUVMO with levodopa did not increase their levodopa dose; 94% taking JUVMO without levodopa did not start it. Reported adverse events included nausea and dizziness. Safety information also warns of low blood pressure, hallucinations and uncontrolled movements.
Allergan Aesthetics (ABBV) launched AA Signature™ in the United States on September 22, 2026, debuting its first multimodal consultation approach, AA Signature: SKIN360.
AA Signature is described as a collection of structured, patient-centric facial assessment protocols that use Allergan Medical Institute resources and Allergan Aesthetics products to support comprehensive aesthetic consultations. The initial SKIN360 protocol focuses on patients seeking smoother, more hydrated skin and may incorporate SKINVIVE by JUVÉDERM®, SkinMedica® HA5® Hydra Collagen Hydrator with Vegan Collagen, and BOTOX® Cosmetic (onabotulinumtoxinA). Research cited shows 96% of patients are interested in comprehensive assessments, practices using multimodal planning see 68% higher patient retention than single-concern approaches, and 8 out of 10 patients proceed with treatment after such assessments.
The company plans additional AA Signature consultation protocols through 2027 targeting concerns such as lift, structure, skin firmness, and facial definition. A footnote states the safety and efficacy of the combined use of SKIN360 products have not been studied.
AbbVie (ABBV) received European Commission approval for RINVOQ (upadacitinib) 15 mg tablet and 1 mg/mL oral solution to treat active polyarticular juvenile idiopathic arthritis in patients aged two years and older who have had an inadequate response or intolerance to at least one DMARD.
The drug may be used as monotherapy or with methotrexate. Approval is based on the open‑label Phase 1 SELECT‑YOUTH study and adult rheumatoid arthritis data. In SELECT‑YOUTH (N=122), ACR pediatric 70 response reached 66.4% at week 12 and 79.5% at week 48, while remission (JADAS27‑CRP ≤1) reached 23.0% and 43.4%, respectively. Mean C‑HAQ functional scores improved by −0.46 at week 12 and −0.64 at week 48; pain scores improved by −26.2 and −30.8. No new safety risks, major cardiovascular or thrombotic events, malignancies, deaths, or growth/development impacts were observed in the study. RINVOQ is now approved in the EU for 11 indications.
AbbVie (ABBV) and Iambic announced a multi-year collaboration to apply Iambic's AI-driven molecular superintelligence platform to discover and develop small molecule therapies in immunology, neuroscience and oncology.
The partnership will use Iambic technologies including Enchant v3, a next-generation multimodal transformer model trained on over 6,000 molecular properties, and NeuralPLexer to optimize many drug candidate properties simultaneously, aiming to improve prediction accuracy and shorten discovery timelines. AbbVie plans to pair these tools with its therapeutic area expertise to design better molecules more efficiently and raise the probability of success in R&D. Under the agreement, Iambic receives an upfront payment and is eligible for success-based milestones and tiered royalties on net sales of products arising from the collaboration.